Participant flow

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia · Source last updated 2026-03-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Bortezomib 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m\^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily). Bortezomib: 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab: 375 mg/m\^2 IV on Day 8 and 22. Valacyclovir: 500 mg orally daily (or acyclovir 200 mg orally twice daily)

   id

   FG000

   title

   Bortezomib + Rituximab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Lack of Efficacy

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Unable to collect SCT

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Progressive Disease

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         37

      comment

      (Additonal cycle 3); Bortezomib 1.6 mg/m2, Rituximab 375 mg/m2 (1 additional cycle)

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      Inadequate Response to First Two Cycles

   3. achievements

      1. group Id

         FG000

         num Subjects

         12

      comment

      Rituximab 375 mg/m\^2, Cyclophosphamide 100 mg/m\^2, Doborubicine 9 mg/m\^2/day, dexamethasone 40 mg/day (2 cycles)

      type

      Inadequate Response to First 3 Cycles

   4. achievements

      1. group Id

         FG000

         num Subjects

         30

      comment

      \+ 1 cycle of 2CdA 3.0 mg/m2, cyclophosphamide 60 mg/m2, rituximab 375 mg/m2

      type

      If Adequate Response to First Two Cycles-participants Proceed to Stem Cell Collection

   5. achievements

      1. group Id

         FG000

         num Subjects

         28

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

46 Participants consented, 9 screen failures.

recruitment Details

Recruitment Period: August 2006- March 2013

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice